Bausch + Lomb Corp sees a notable increase in stock value, reflecting positive market sentiment.
Bausch + Lomb Corp (BLCO.TO) experienced a 1.97% rise in its stock price during the last trading session, closing at CA$22.83. This uptick comes amidst a backdrop of increasing interest in the ophthalmology devices market, which is projected to grow significantly over the next few years.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.09B
52W high
$25.70
52W low
$18.24
1W change
-7.90%
Beta
0.56
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to fall 15.9% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$18.82
-15.9% Upside
Current Price
C$22.39
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
33.5%
Annualized
90-Day Vol
31.0%
Annualized
Trend (90d)
-13.5%
Annualized drift
90d Mean
C$21.34
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$22.03 | C$19.63 โ C$24.73 |
| 60 trading days | C$21.68 | C$18.41 โ C$25.53 |
| 90 trading days | C$21.34 | C$17.47 โ C$26.06 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: The recent gain in Bausch + Lomb's stock highlights the company's potential as a key player in the expanding ophthalmology market, driven by rising demand for innovative eye care solutions.
1.97% Gain in Stock Price
Bausch + Lomb's stock closed at CA$22.83, reflecting investor optimism amidst a growing ophthalmology market.
Bull case
The ophthalmology devices market is expected to grow from $56.61 billion in 2025 to $63.23 billion in 2026. This presents a significant opportunity for Bausch + Lomb as it continues to innovate and expand its product offerings.
Bear case
Despite the positive market trends, Bausch + Lomb has faced recent setbacks in clinical trials, which could impact its future growth and investor confidence. If the company struggles to deliver on its pipeline promises, it may face challenges ahead.
Market Growth Driving Stock Performance
The ophthalmology devices market is on a robust growth trajectory, expected to reach $63.23 billion in 2026. This growth is driven by factors such as an aging population and increasing prevalence of eye disorders. This trend bodes well for Bausch + Lomb as it positions itself as a leader in the sector.
Recent Clinical Developments
Despite recent setbacks in clinical trials, including the discontinuation of an experimental glaucoma treatment, Bausch + Lomb's diversified pipeline remains a strength. The company continues to focus on innovative solutions in eye care, which could enhance its market position.
Investor Sentiment and Future Outlook
The recent stock gain reflects positive investor sentiment, as many see Bausch + Lomb as well-positioned to capitalize on market trends. However, ongoing scrutiny of its clinical pipeline and market performance will be crucial for sustaining this momentum.
Advertisement
